Learning

March 29, 2019

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA GM6135 increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 29/March/2019, 10.41 am

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center […]
March 28, 2019

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA B3GALT5-AS1 increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 28/March/2019, 7.07 am

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center […]
March 28, 2019

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA PMS2L2 increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 28/March/2019, 5.58 am

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center […]
March 12, 2019

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA PVT1 increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 12/March/2019, 9.18 am

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center […]